# A Study of Ad26.COV2.S in Adults (COVID-19)

> **NCT04436276** · PHASE1,PHASE2 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 1085 (actual)

## Conditions studied

- Covid-19 Prevention

## Interventions

- **BIOLOGICAL:** Ad26.COV2.S
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04436276
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-15
- **Primary completion:** 2023-02-21
- **Final completion:** 2023-02-21
- **Target enrollment:** 1085 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04436276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04436276, "A Study of Ad26.COV2.S in Adults (COVID-19)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04436276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*